4X more urate deposits were found using DECT vs through clinical examination3
*According to a long-term follow-up of 24 patients receiving a mean daily dose of 320 mg allopurinol.
KRYSTEXXA has not been studied to reverse damage to any of the body’s organs.
sUA, serum uric acid.
Potential to
2020 ACR Guidelines: When treating, ULT titration should occur over a reasonable timeframe (eg, weeks to months, not months to years) to prevent treatment inertia8†
†TTreatment inertia is when adjustments are not made to current therapy when it fails to meet patient treatment goals.17
‡The primary efficacy endpoint was an sUA concentration of <6 mg/dL at each of the last 3 monthly measurements.16
ACR, American College of Rheumatology; DECT, dual-energy computed tomography; ULT, urate-lowering therapy.
Percentages of patients treated with allopurinol and febuxostat who failed to reach a target sUA level of <6 mg/dL16‡
300 mg allopurinol/day for 52 weeks (n=251)
80 mg febuxostat/day for 52 weeks (n=255)
Interested in learning more about uncontrolled gout and sUA? Connect with the KRYSTEXXA team to discuss.
See if your patients fit the criteria for uncontrolled gout.
Occupation:
Accountant
55-year-old with hypertension diagnosed with gout 4 years ago
Actor portrayal, not actual patient.
Occupation:
Middle school teacher
52-year-old with diabetes diagnosed with gout 15 years ago
Actor portrayal, not actual patient.
Occupation:
Stay-at-home parent
43-year-old diagnosed with gout over 20 years ago
Real patient.
Gout Flares: An increase in gout flares is frequently observed upon initiation of anti-hyperuricemic therapy, including KRYSTEXXA. Gout flare prophylaxis with a non-steroidal anti-inflammatory drug (NSAID) or colchicine is recommended starting at least 1 week before initiation of KRYSTEXXA therapy and lasting at least 6 months, unless medically contraindicated or not tolerated.
Congestive Heart Failure: KRYSTEXXA has not been formally studied in patients with congestive heart failure, but some patients in the pre-marketing placebo-controlled clinical trials experienced exacerbation. Exercise caution in patients who have congestive heart failure and monitor patients closely following infusion.
The most commonly reported adverse reactions (≥5%) are:
KRYSTEXXA co-administration with methotrexate trial:
KRYSTEXXA with methotrexate: gout flares, arthralgia, COVID-19, nausea, and fatigue; KRYSTEXXA alone: gout flares, arthralgia, COVID-19, nausea, fatigue, infusion reaction, pain in extremity, hypertension, and vomiting.
KRYSTEXXA pre-marketing placebo-controlled trials:
gout flares, infusion reactions, nausea, contusion or ecchymosis, nasopharyngitis, constipation, chest pain, anaphylaxis, and vomiting.
KRYSTEXXA® (pegloticase) is indicated for the treatment of chronic gout in adult patients who have failed to normalize serum uric acid and whose signs and symptoms are inadequately controlled with xanthine oxidase inhibitors at the maximum medically appropriate dose or for whom these drugs are contraindicated.
Limitations of Use: KRYSTEXXA is not recommended for the treatment of asymptomatic hyperuricemia.
Please see Full Prescribing Information, including Boxed Warning.